Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1B | P47901 | 17/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | GPR6 | P46095 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1875849 | 0.94 | AVPR1B (0.55) | AVPR1BCYP3A4GPR6 | |
| SCHEMBL1877702 | 0.92 | AVPR1B (0.68) | AVPR1BCYP3A4 | |
| SCHEMBL1878467 | 0.90 | AVPR1B (0.51) | AVPR1BCYP3A4GPR6RXFP1 | |
| SCHEMBL1871972 | 0.89 | AVPR1B (0.58) | AVPR1BCYP3A4GPR6MAPT | |
| SCHEMBL1878006 | 0.89 | AVPR1B (0.49) | AVPR1BCYP3A4GPR6HPGDSMN1; SMN2 | |
| SCHEMBL1876483 | 0.88 | AVPR1B (0.58) | AVPR1BCYP3A4GPR6SMN1; SMN2 | |
| SCHEMBL1872081 | 0.86 | AVPR1B (0.68) | AVPR1BCYP3A4 | |
| SCHEMBL1872001 | 0.86 | AVPR1B (0.57) | AVPR1BCYP3A4GPR6 | |
| SCHEMBL1875984 | 0.86 | AVPR1B (0.55) | AVPR1BCYP3A4GPR6 | |
| SCHEMBL17261101 | 0.85 | AVPR1B (0.53) | AVPR1BCYP3A4GPR6HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2227463-B1 | SUBSTITUTED OXINDOLE-DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT ILLNESSES | ABBVIE DEUTSCHLAND (DE) | 2016-08-17 | — | — | EP | claimed |
| US-9238642-B2 | Substituted oxindole-derivatives and the use thereof for the treatment of vasopressin-dependent illnesses | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-19 | — | — | US | claimed |
| US-8629148-B2 | Substituted oxindole-derivatives and the use thereof for the treatment of vasopressin-dependent illnesses | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-01-14 | — | — | US | claimed |
| EP-2227463-B1 | SUBSTITUTED OXINDOLE-DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT ILLNESSES | ABBVIE DEUTSCHLAND (DE) | 2016-08-17 | — | — | EP | disclosed |
| US-9238642-B2 | Substituted oxindole-derivatives and the use thereof for the treatment of vasopressin-dependent illnesses | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-19 | — | — | US | disclosed |
| US-20140303138-A1 | SUBSTITUTED OXINDOLE-DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT ILLNESSES | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-10-09 | — | — | US | disclosed |
| US-8629148-B2 | Substituted oxindole-derivatives and the use thereof for the treatment of vasopressin-dependent illnesses | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20110105454-A1 | SUBSTITUTED OXINDOLE-DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT ILLNESSES | ABBOTT GMBH & CO. KG (DE) | 2011-05-05 | — | — | US | disclosed |
| EP-2227463-A1 | SUBSTITUTED OXINDOLE-DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT ILLNESSES | Abbott GmbH & Co. KG (DE) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009083559-A1 | SUBSTITUTED OXINDOLE-DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT ILLNESSES | ABBOTT GMBH & CO. KG (DE) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303138-A1 | SUBSTITUTED OXINDOLE-DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT ILLNESSES | AVPR2, AVPR1B, AVPR1A | AVPR1B 2/4885CYP3A4 1566/4885GPR6 1144/4885 |
| US-20110105454-A1 | SUBSTITUTED OXINDOLE-DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT ILLNESSES | AVPR2, AVPR1B, AVPR1A | AVPR1B 2/4885CYP3A4 1566/4885GPR6 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.